New Weight-Loss Drug Launch Still Years Away

Viking Therapeutics expects its obesity drug to be available in two and a half years as clinical trials progress.

Updated on Oct. 29, 2026 in Weight Loss

Isometric editorial illustration of clinical glass vials, representing the research and development phase of a new pharmaceutical treatment. — Viking Therapeutics reported a $183.2 million net loss as the company continues clinical trials for its obesity drug, VK2735. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to deliver on long-term drug development timelines?

Viking Therapeutics reported a third-quarter net loss of $183.2 million as the company accelerates development of its obesity drug, VK2735. The firm estimates the drug launch remains two and a half years away.

Why it matters

The company is prioritizing heavy investment in clinical trials to ensure long-term profitability and commercial viability for its weight-loss program. These expenses are central to the development timeline for patients awaiting new treatment options.

Viking Therapeutics reported a quarterly net loss of $183.2 million, largely driven by $166.8 million in research and development spending. Success of the VK2735 program depends on results from four ongoing Phase 3 clinical trials, which remain under investigation.

The players

Viking Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders, including weight management.

Brian Lian

The Chief Executive Officer of Viking Therapeutics who manages the company's research pipeline and strategic development timeline.

The details

Viking is funding the commercialization and clinical infrastructure needed to bring the injectable drug VK2735 to market. The company is using capital from stock and convertible-note offerings to maintain operations while trial and manufacturing costs rise. Management is specifically focusing on establishing gross margins that will support a sustainable long-term business model.

September 30, 2026: Company fiscal third quarter ended.
October 28, 2026: Viking Therapeutics held its earnings call.
Early 2027: First patients are expected to enter extension studies.
Q1 2027: Planned start of a 28-day multiple-dose study for VK3019.

Health Landscape

Viking Therapeutics is positioning its pipeline to enter the highly competitive market for GLP-1 receptor agonist obesity drugs. This development follows a period of rapid industry growth and substantial investment in therapies targeting weight management.

Readers tracking new obesity treatments should note that while development is ongoing, commercial availability of VK2735 is not expected for approximately 30 months. It is worth discussing current weight management options with your doctor while monitoring for future study results.

The takeaway

Viking Therapeutics is continuing to scale its research operations to prepare for a multi-year drug development cycle. Readers interested in emerging therapies should track future trial updates for data on long-term safety and efficacy.

What happens next

A 28-day multiple-dose study of VK3019 is scheduled to begin in the first quarter of 2027, followed by the enrollment of patients into VK2735 extension studies in early 2027.